Search

pms-Risedronate

pms-Risedronate

risedronic acid

Manufacturer:

Pharmascience

Distributor:

T-BOMA
Concise Prescribing Info
Contents
Risedronate Na
Indications/Uses
Treatment & prevention of osteoporosis in postmenopausal women. Treatment of osteoporosis in men, to improve bone mineral density.
Click to view pms-Risedronate detailed prescribing information
Dosage/Direction for Use
35 mg once a wk.
Click to view pms-Risedronate detailed prescribing information
Overdosage
View pms-Risedronate overdosage for action to be taken in the event of an overdose.
Administration
Should be taken on an empty stomach.
Contraindications
Hypersensitivity. Hypocalcemia.
Click to view pms-Risedronate detailed prescribing information
Special Precautions
Effectively treat hypocalcemia & other disturbances of bone & mineral metabolism before starting therapy. May cause upper GI disorders eg, dysphagia, esophagitis, esophageal ulcer, & gastric ulcer. Reports of osteonecrosis of the jaw (ONJ). Perform a routine oral examination prior to treatment. Perform routine dental check-ups & avoid invasive dental procedures while on treatment. Reports of atypical, low-energy, or low trauma fractures of the femoral shaft. Discontinue use in case of severe & occasionally incapacitating bone, joint, &/or muscle pain; ocular disturbances including conjunctivitis, uveitis, episcleritis, iritis, & scleritis. Not recommended for use in patients w/ severe renal impairment (CrCl <30 mL/min). Not intended for use during pregnancy & lactation.
Click to view pms-Risedronate detailed prescribing information
Adverse Reactions
Musculoskeletal pain; abdominal pain, dyspepsia, nausea, diarrhea.
Click to view pms-Risedronate detailed prescribing information
Drug Interactions
Antacids & medications containing polyvalent cations (eg, Ca, Mg, Al & Fe) interferes w/ risedronate Na absorption. Increased risk of developing ONJ w/ angiogenesis inhibitors. Interference w/ use of bone-imaging agents.
Click to view pms-Risedronate detailed prescribing information
Storage
View pms-Risedronate storage conditions for details to ensure optimal shelf-life.
Description
View pms-Risedronate description for details of the chemical structure and excipients (inactive components).
Action
View pms-Risedronate mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BA07 - risedronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Presentation/Packing
Form
pms-Risedronate tab 35 mg
Packing/Price
1 × 4's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in